Advertisement

ASH 2022: Talquetamab for Relapsed or Refractory Multiple Myeloma
Posted: 01/03/2023 | By: Sarah Campen, PharmD

Results of the phase I/II MonumenTAL-1 trial of talquetamab, a bispecific antibody, in patients with relapsed or refractory multiple myeloma were presented at the 2022 ASH Annual Meeting and Exposition (Abstract 157).

Question 1 of 5

Talquetamab is a bispecific antibody targeting:

Choose 1

A
G protein-coupled receptor family B group 2 member C and CD19
B
G protein-coupled receptor family A group 3 member B and CD3
C
G protein-coupled receptor family D group 4 member D and CD16
D
G protein-coupled receptor family C group 5 member D and CD3

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage